A Drug That Outlasted Its Own Controversies—and Still Doesn't Come Up in Clinical Practice
Albendazole has weathered manufacturing disruptions, supply chain failures, and years of inconsistent regulatory attention—and emerged with its OTC status intact. Yet despite this track record of institutional scrutiny, the drug remains conspicuously absent from routine clinical conversations, a paradox rooted in medical education gaps and structural inertia.